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Polymyositis and myocarditis very rarely develop during chemotherapy for thymoma. Most
reported cases of myocarditis and polymyositis associated with thymoma were found at autopsy
of patients who died of acute progression of myocarditis. We describe our experience with a
64-year-old man who had recurrent thymoma accompanied by polymyositis and myocarditis.
Lower-extremity myalgia and palpitations developed on day 25 of chemotherapy with weekly
paclitaxel. Steroid pulse therapy was effective for the management of polymyositis and
myocarditis associated with thymoma. Polymyositis and myocarditis after paclitaxel mono-
therapy have not been documented previously. Whether paclitaxel induced polymyositis and
myocarditis is unclear and these symptoms might have been a paraneoplastic phenomenon
associated with thymoma. However, our experience suggested that patients with thymoma who
received paclitaxel-based chemotherapy should be carefully observed for polymyositis and
myocarditis. If such patients have high serum creatine phosphokinase and troponin levels,
steroid pulse therapy should be considered without delay.
& 2013 The Authors. Published by Elsevier Ltd. All rights reserved.1. Introduction
Polymyositis and myocarditis very rarely develop during
chemotherapy for thymoma. Most reported cases inThe Authors. Published by Elsevi
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moto).myocarditis and polymyositis associated with thymoma have
been found at autopsy of patients who died of acute
progression of myocarditis [1–4].
2. Presentation of case
A 64-year-old man was given a diagnosis of thymoma, myasthe-
nia gravis, and Isaccs syndrome and received an extended
thymectomy (WHO typeAB) in 2005. The patient was subse-
quently followed up at regular intervals and received oral
cyclosporine (100 mg/day) and prednisolone (7 mg/day) to
treat myasthenia gravis and Isaccs syndrome. On exacerbations
of Isaccs syndrome, steroid pulse therapy or plasmapheresis waser Ltd. All rights reserved.
Fig. 1 Clinical course.
T. Yamamoto et al.10performed. There was no elevation of the serum creatine
phosphokinase (CK) level at that time. In July, 2011, a follow-
up computed tomographic scan revealed multiple pleural
nodules. A biopsy of the nodules yielded a diagnosis of recurrent
thymoma. Chemotherapy was initiated. Because the patient
wanted to receive chemotherapy on an outpatient basis, a
regimen of weekly paclitaxel 80 mg/m2 was selected. Lower-
extremity myalgia and palpitations developed on day 25 of
chemotherapy and persisted. Because laboratory tests revealed
elevated serum levels of CK (6353 U/l), CK-MB (246 U/l),
myoglobin (4432 ng/ml), and troponin I (1.539 ng/ml), and an
electrocardiogram showed frequent supraventricular extrasys-
toles, he was hospitalized for a suspected diagnosis of poly-
myositis and myocarditis associated with thymoma. The serum
antiacetylcholine receptor antibody level (0.9 nmol/l) was not
elevated as compared with previously. Because myalgia of the
extremities worsened after admission, he received steroid pulse
therapy (methylprednisolone 1 g/day intravenously for 3 days).
After that, serum CK and myoglobin levels decreased (Fig. 1)
and symptoms of myalgia and palpitations rapidly improved. He
was discharged on the 12th day after steroid pulse therapy.
Subsequently, a computed tomographic scan showed no
response to paclitaxel therapy, and he refused further che-
motherapy. He was observed, with no treatment for thymoma.
There was no further recurrence of polymyositis and myocardi-
tis up to patient's death in August 2012.
3. Discussion
Polymyositis and myocarditis have rarely been associated
with chemotherapy [1–3] or tacrorimus [4], or thymectomy
[5] during the clinical course of thymoma. To our knowledge,
only three cases of myocarditis and polymyositis associated
with chemotherapy for thymoma have been reported previously
[1–3]. These patients received combination chemotherapy with
carboplatin and paclitaxel. Our patient was given paclitaxel
monotherapy. Polymyositis and myocarditis after paclitaxel
monotherapy have not been documented previously. Whether
paclitaxel induced polymyositis and myocarditis is unclear and
these symptoms might have been a paraneoplastic phenomenon
associated to thymoma. However, our experience suggests
that patients with thymoma who received paclitaxel-based
chemotherapy should be carefully observed for polymyositis
and myocarditis.
Most reported cases of myocarditis and polymyositis
associated with thymoma were diagnosed at autopsy, afterthe patients had died of rapid progression of myocarditis in
the absence of effective therapy. The histopathological
diagnosis at autopsy of nearly all reported cases was giant
cell myocarditis. None of these patients had an antemortem
diagnosis of giant cell myocarditis with thymoma owing to
the risks of associated with biopsy and the fulminant course
of disease. Our patient also did not have a histopathological
diagnosis of myocarditis, but polymyositis and myocarditis
were diagnosed clinically on the basis of the elevated serum
CK and troponin levels and the presence of myalgia and
arrhythmias. Steroid therapy has been used to treat poly-
myositis and myocarditis in patients with thymoma, but few
have responded. Koul et al. reported a case of giant cell
myocarditis with thymoma that responded to steroids and
plasmapheresis [6]. In our patient, only steroid pulse therapy
was effective against polymyositis and myocarditis associated
with thymoma, myasthenia gravis, and Isaccs syndrome.
4. Conclusion
Chemotherapy with paclitaxel might trigger the polymyosi-
tis and myocarditis. In patients with thymoma who have
high serum CK and troponin levels, steroid pulse therapy
should be considered without delay.
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